Business

Systematic, data-driven science coverage · Friday, July 31, 2026
More from Business
Business

Coherus Oncology raises USD 50.1m in public offering of common stock

Redwood City, California-based Coherus Oncology, Inc. (NASDAQ: CHRS) announced the pricing of an underwritten Coherus Oncology public offering of common...

Mar 31
Business

Yatiri Bio options global rights to Oscotec's multikinase inhibitor denfivontinib for AML

Yatiri Bio, a San Diego-based precision medicine company, has entered an exclusive global option to in-license agreement with South Korea's Oscotec for...

Mar 31
Business

Shionogi Acquires Apnimed's SASS Joint Venture Stake for USD 150m to Consolidate Sleep Medicine Portfolio

Shionogi & Co., Ltd. has entered a definitive agreement to acquire Apnimed, Inc.'s 50% ownership of the Shionogi-Apnimed Sleep Science, LLC (SASS) joint...

Mar 31
Business

Opus Genetics raises USD 25m in private placement

U.S.-based Opus Genetics (Nasdaq: IRD) announced a USD 25 million private placement financing through the sale of Series B Non-Voting Convertible Preferred...

Mar 31
Business

Ovid Therapeutics raises USD 60m in private placement to expand epilepsy pipeline

Ovid Therapeutics Inc. (Nasdaq: OVID), a New York-based biopharmaceutical company developing small molecule therapies for neurological disorders, announced...

Mar 31
Business

Seaport Therapeutics Receives Up to $15M ARPA-H Award to Advance Lymphatic-Targeted Oral Prodrug

Boston-based Seaport Therapeutics, a clinical-stage company focused on neuropsychiatric medicines, has received a non-dilutive award of up to USD 15 million...

Mar 31
Business

Altesa BioSciences Closes USD 75 Million Series B to Advance Rhinovirus Antiviral Therapy

Altesa BioSciences, a clinical-stage company headquartered in Atlanta focused on developing antiviral therapies for chronic lung disease, has closed an...

Mar 31
Business

Ovid Therapeutics raises USD 60m in private placement

Ovid Therapeutics Inc. (Nasdaq: OVID), a New York-based biopharmaceutical company developing small molecule therapies for brain disorders, announced a USD...

Mar 31
The AllSci BriefSystematic R&D and deal news. Daily.
Business

Xenon Pharmaceuticals raises USD 747.5m in upsized public offering

Canada-based Xenon Pharmaceuticals Inc. (Nasdaq: XENE), a neuroscience-focused biopharmaceutical company with offices in Vancouver and Boston, announced the...

Mar 31
Business

Insilico Medicine and Liquid AI partner on lightweight AI foundation models for drug discovery

Insilico Medicine, a clinical-stage AI-driven drug discovery company headquartered in Hong Kong, and Liquid AI, a Cambridge, Massachusetts-based AI...

Mar 31
Business

Liminatus Pharma raises USD 4m in best-efforts public offering

Cerritos, California-based Liminatus Pharma (NASDAQ: LIMN) announced the pricing of a best-efforts public offering expected to generate approximately USD...

Mar 31
Business

Innovent and Lilly's $8.5B Oncology Deal Sparks Global Cancer Research Collaboration

Innovent and Lilly Forge Strategic Alliance to Advance Global Oncology and Immunology Research

Mar 30
Business

Gilgamesh Pharma Raises USD 60M Series A to Advance Neuropsychiatric Drug Pipeline

Gilgamesh Pharma, a clinical-stage neuroscience company headquartered in New York, has closed an oversubscribed USD 60 million Series A financing round to...

Mar 31
Business

Artelo Biosciences raises USD 11m in private placement

Artelo Biosciences, Inc. (Nasdaq: ARTL), a clinical-stage pharmaceutical company based in Solana Beach, California, announced an Artelo $11 million private...

Mar 31
Business

Excalipoint Therapeutics Closes Oversubscribed $68.7 Million Seed Round for T-Cell Engager Therapies

Excalipoint Therapeutics, a Shanghai-based biotechnology company focused on next-generation T-cell engager therapies for cancer and autoimmune diseases, has...

Mar 31